Gene Activity List

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Gene Compound Experiment Study Pathway Assay Report Bug Request Feature
Gene Activity List
You are on Page 12 of 1714:
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Gene Compound Assay Inh Ic50 Ki View
sodium channel, voltage-gated, type III, beta RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
sodium channel, voltage-gated, type I, alpha RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
sodium channel, voltage-gated, type IX, alpha RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
sodium channel, voltage-gated, type VII, alpha RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
amiloride-sensitive cation channel 5, intestinal RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
sodium channel, voltage-gated, type III, beta RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
sodium channel, voltage-gated, type XI, alpha RESERPINE Sodium Channel, Site 2 100% .774uM .706uM View
sodium channel, voltage-gated, type IX, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type VII, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
amiloride-sensitive cation channel 5, intestinal QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type III, beta QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type XI, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type I, beta QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type 10, alpha polypeptide QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type IV, alpha polypeptide QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type V, alpha polypeptide QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type II, beta QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, nonvoltage-gated 1 alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, nonvoltage-gated 1 gamma QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, nonvoltage-gated 1 beta QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type XI, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, nonvoltage-gated 1, gamma QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, nonvoltage-gated 1, delta QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, nonvoltage-gated 1 alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type X, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type IX, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage gated, type VIII, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type VII, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type IV, beta QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel, voltage-gated, type IV, alpha QUINACRINE Sodium Channel, Site 2 100% 1.275uM 1.163uM View
sodium channel associated protein 1 SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel associated protein 2 SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type III, beta SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type I, alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type IX, alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type VII, alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
amiloride-sensitive cation channel 5, intestinal SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type III, beta SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type XI, alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type I, beta SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type 10, alpha polypeptide SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type IV, alpha polypeptide SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type V, alpha polypeptide SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type II, beta SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, nonvoltage-gated 1 alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, nonvoltage-gated 1 gamma SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, nonvoltage-gated 1 beta SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type XI, alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, nonvoltage-gated 1, gamma SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, nonvoltage-gated 1, delta SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, nonvoltage-gated 1 alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type X, alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type IX, alpha SAQUINAVIR Sodium Channel, Site 2 100% .755uM .677uM View
sodium channel, voltage-gated, type IV, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel associated protein 1 LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel associated protein 2 LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type III, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type I, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type IX, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type VII, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
amiloride-sensitive cation channel 5, intestinal LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type III, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type XI, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type I, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type 10, alpha polypeptide LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type IV, alpha polypeptide LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type V, alpha polypeptide LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type II, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, nonvoltage-gated 1 alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, nonvoltage-gated 1 gamma LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, nonvoltage-gated 1 beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type XI, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, nonvoltage-gated 1, gamma LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, nonvoltage-gated 1, delta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, nonvoltage-gated 1 alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type X, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type IX, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage gated, type VIII, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type VII, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type IV, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type IV, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type III, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type II, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type II, alpha 2 LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type I, beta LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
sodium channel, voltage-gated, type I, alpha LOPERAMIDE Sodium Channel, Site 2 100% .093uM .085uM View
adrenergic receptor, alpha 1b MEPAZINE Adrenergic alpha1B 100% .061uM .034uM View
calcium channel, voltage-dependent, gamma subunit 8 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, gamma subunit 7 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, gamma subunit 6 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, gamma subunit 5 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, gamma subunit 4 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, gamma subunit 3 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
adrenergic receptor, alpha 2a O-ANISIDINE Imidazoline I2, Central 31% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 2 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, gamma subunit 1 MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, beta 4 subunit MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, beta 3 subunit MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, beta 2 subunit MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, alpha 1F subunit MEPAZINE Calcium Channel Type L, Phenylalkylamine 100% 1.546uM 1.503uM View
calcium channel, voltage-dependent, gamma subunit 7 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, gamma subunit 6 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, gamma subunit 5 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, gamma subunit 4 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, gamma subunit 3 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, gamma subunit 2 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, gamma subunit 1 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, beta 4 subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, beta 3 subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, beta 2 subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, alpha 1F subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, L type, alpha 1C subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, beta 1 subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 LACIDIPINE Calcium Channel Type L, Dihydropyridine 100% .0004uM .000257uM View
Protein-tyrosine kinase, Fyn CETYLPYRIDINIUM BROMIDE Protein Tyrosine Kinase, Fyn 100% .298uM NoneNone View
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 CETYLPYRIDINIUM BROMIDE Serotonin Transporter 100% 1.68uM .892uM View
adrenergic receptor, alpha 2b CETYLPYRIDINIUM BROMIDE Adrenergic alpha2B 100% 1.778uM .812uM View
cholinergic receptor, muscarinic 3 CETYLPYRIDINIUM BROMIDE Muscarinic M3 100% .034uM .007297uM View
5-hydroxytryptamine (serotonin) receptor 1A CETYLPYRIDINIUM BROMIDE Serotonin 5-HT1A 100% 2.831uM 1.618uM View
adrenergic receptor, alpha 2b PROMETHAZINE Adrenergic alpha2B 100% .053uM .024uM View
cholinergic receptor, muscarinic 1 PROMETHAZINE Muscarinic M1 100% .014uM .003321uM View
cholinergic receptor, muscarinic 2 PROMETHAZINE Muscarinic M2 100% .035uM .012uM View
cholinergic receptor, muscarinic 4 PROMETHAZINE Muscarinic M4 100% .007576uM .001057uM View
cholinergic receptor, muscarinic 2 CETYLPYRIDINIUM BROMIDE Muscarinic M2 100% .116uM .041uM View
cholinergic receptor, muscarinic 4 CETYLPYRIDINIUM BROMIDE Muscarinic M4 100% .106uM .015uM View
cholinergic receptor, muscarinic 5 CETYLPYRIDINIUM BROMIDE Muscarinic M5 100% .01uM .007277uM View
5-hydroxytryptamine (serotonin) receptor 2C PROMETHAZINE Serotonin 5-HT2C 100% .012uM .006477uM View
5-hydroxytryptamine (serotonin) receptor 2A PROMETHAZINE Serotonin 5-HT2A 100% .067uM .019uM View
protein kinase C, alpha FAMOTIDINE Phorbol Ester 3% NoneNone NoneNone View
cholinergic receptor, muscarinic 5 PROMETHAZINE Muscarinic M5 100% .004603uM .003307uM View
adrenergic receptor, alpha 1b PROMETHAZINE Adrenergic alpha1B 100% .039uM .021uM View
cholinergic receptor, muscarinic 3 PROMETHAZINE Muscarinic M3 100% .02uM .004149uM View
arachidonate 15-lipoxygenase, second type PHENYLHYDRAZINE Lipoxygenase 15-LO 100% 1.666uM NoneNone View
arachidonate 15-lipoxygenase PHENYLHYDRAZINE Lipoxygenase 15-LO 100% 1.666uM NoneNone View
arachidonate 15-lipoxygenase PHENYLHYDRAZINE Lipoxygenase 15-LO 100% 1.666uM NoneNone View
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 PRIMAQUINE Serotonin Transporter 100% .016uM .008405uM View
calcium channel, voltage-dependent, gamma subunit 8 EBASTINE Calcium Channel Type L, Benzothiazepine 100% .0653uM .058uM View
sodium channel associated protein 1 RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel associated protein 2 RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type III, beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type I, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type IX, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type VII, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
amiloride-sensitive cation channel 5, intestinal RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type III, beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type XI, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type I, beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type 10, alpha polypeptide RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type IV, alpha polypeptide RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type V, alpha polypeptide RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type II, beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, nonvoltage-gated 1 alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, nonvoltage-gated 1 gamma RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, nonvoltage-gated 1 beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type XI, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, nonvoltage-gated 1, gamma RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, nonvoltage-gated 1, delta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, nonvoltage-gated 1 alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type X, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type IX, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage gated, type VIII, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type VII, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type IV, beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type IV, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type III, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type II, beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type II, alpha 2 RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type I, beta RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
sodium channel, voltage-gated, type I, alpha RALOXIFENE Sodium Channel, Site 2 100% .527uM .48uM View
5-hydroxytryptamine (serotonin) receptor 2B RALOXIFENE Serotonin 5-HT2B 100% .355uM .226uM View
sodium channel, voltage-gated, type IV, beta BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View
sodium channel associated protein 1 BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View
sodium channel associated protein 2 BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View
sodium channel, voltage-gated, type III, beta BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View
sodium channel, voltage-gated, type I, alpha BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View
sodium channel, voltage-gated, type IX, alpha BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View
sodium channel, voltage-gated, type VII, alpha BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View
amiloride-sensitive cation channel 5, intestinal BENZETHONIUM CHLORIDE Sodium Channel, Site 2 100% .254uM .232uM View